Lantheus Holdings (NasdaqGM:LNTH) Sees 19% Surge Following 2024 Earnings US$1.534 Billion Sales Increase
Lantheus Holdings (NasdaqGM:LNTH) saw an 18.83% increase in its share price over the past week, driven by recent corporate updates and market trends. The company announced its 2024 earnings, reporting ...
William Blair Remains a Hold on Lantheus (LNTH)
William Blair analyst Andy Hsieh maintained a Hold rating on Lantheus (LNTH – Research Report) today. The company’s shares closed today at ...
Truist Financial Sticks to Its Hold Rating for Treace Medical Concepts (TMCI)
Truist Financial analyst Richard Newitter maintained a Hold rating on Treace Medical Concepts (TMCI – Research Report) today and set a price ...
snmjournals.org17h
Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually)
Following the Food and Drug Administration’s approval of Lutathera and Pluvicto in 2018 and 2022, respectively, we predicted ...
The Lancet7h
Destroy or delay: hormonal therapy in oligometastatic prostate cancer
Since the existence of the oligometastatic disease state was posited three decades ago,1 there has been interest in ...
PharmiWeb18h
Radiopharmaceuticals Market Size to Register $9.75 Billion Globally, by 2030, at 9.4% CAGR Growth
Global Radiopharmaceuticals Market is valued at USD 5.2 Billion in 2022.Global Radiopharmaceuticals Market valuation to reach ...
March 2025's Noteworthy Stocks Estimated Below Intrinsic Value
As February 2025 comes to a close, the U.S. stock market has experienced a mixed performance with major indexes posting losses for the month despite a late surge fueled by easing inflation concerns.